Belite Bio (BLTE) H.C. Wainwright 6th Annual Ophthalmology Virtual Conference summary

Key insights on novel therapies for inherited retinal disorders

• Disease-modifying therapies are best suited for early and intermediate stages, while optogenetics and restorative approaches are more relevant for advanced disease with severe photoreceptor loss.

• Structural preservation in Stargardt disease is expected to translate into long-term functional benefits, though short-term trials may not capture these changes; endpoints like reading speed and visual acuity are important.

• In advanced retinitis pigmentosa, functional endpoints such as mobility, object localization, and independence are prioritized over visual acuity for assessing therapeutic benefit.

• The DRAGON trial for tinlarebant showed a 35.7% reduction in macular lesion growth, a substantial effect compared to other treatments for geographic atrophy, with benefits expected to be more pronounced over decades.

• Efficacy of tinlarebant did not show dependency on ABCA4 genotype, suggesting broad applicability across Stargardt patients.

Clinical and patient impact

• Tinlarebant is recommended for timely intervention, potentially even before significant functional loss, to maximize preservation of photoreceptors.

• MCO-010 optogenetic therapy targets inner retinal cells, restoring vision in advanced RP patients, with improvements seen in visual acuity, mobility, and shape discrimination.

• All patients in MCO-010 trials showed improvement in at least one key efficacy endpoint, with thicker retinas correlating with better outcomes.

• Both therapies are considered promising, with tinlarebant slowing disease progression and MCO-010 restoring vision in advanced cases.

• Early identification and referral of patients is expected to improve with increased awareness among specialists.

Safety, monitoring, and durability

• Tinlarebant's safety profile is manageable, with most adverse events mild and resolving during treatment; delayed dark adaptation and xanthopsia are transient and manageable with patient education.

• Routine monitoring for tinlarebant may involve six-monthly retinal imaging, with little need for frequent serum or liver testing.

• MCO-010 gene therapy demonstrates durable efficacy, with four-year data showing sustained benefit and no serious adverse events related to treatment.

• Bilateral functional improvement has been observed after unilateral MCO-010 administration, attributed to vector transfer via the optic chiasm.